ES2032378T3 - Procedimiento para preparar una proteina de fusion. - Google Patents

Procedimiento para preparar una proteina de fusion.

Info

Publication number
ES2032378T3
ES2032378T3 ES198686116140T ES86116140T ES2032378T3 ES 2032378 T3 ES2032378 T3 ES 2032378T3 ES 198686116140 T ES198686116140 T ES 198686116140T ES 86116140 T ES86116140 T ES 86116140T ES 2032378 T3 ES2032378 T3 ES 2032378T3
Authority
ES
Spain
Prior art keywords
dna
preparing
procedure
fusion protein
fusion proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198686116140T
Other languages
English (en)
Inventor
Paul Dr. Habermann
Friedrich Dr. Wengenmayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2032378T3 publication Critical patent/ES2032378T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PARA OBTENER PROTEINAS DE FUSION, RESULTA ADECUADO UN "LECTOR ABIERTO" DEL ADN QUE CODIFICA LA INTERLEUKINA-2 (IL-2). PARA ELLO ES SUFICIENTE UNA SECUENCIA PARCIAL DEL ADN QUE CORRESPONDE APROXIMADAMENTE A LOS 100 PRIMEROS AMINOACIDOS DEL ADN. EL GEN PARA LA PROTEINA QUE SE PRETENDE OBTENER PUEDE DISPONERSE ANTES O DESPUES DEL "LECTOR ABIERTO". SE OBTIENEN PROTEINAS DE FUSION POCO SOLUBLES O INSOLUBLES QUE SE PUEDEN SEPARAR FACILMENTE DE LAS PROTEINAS SOLUBLES DEL HUESPED.
ES198686116140T 1985-11-27 1986-11-21 Procedimiento para preparar una proteina de fusion. Expired - Lifetime ES2032378T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853541856 DE3541856A1 (de) 1985-11-27 1985-11-27 Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens

Publications (1)

Publication Number Publication Date
ES2032378T3 true ES2032378T3 (es) 1993-02-16

Family

ID=6286938

Family Applications (3)

Application Number Title Priority Date Filing Date
ES198686116140T Expired - Lifetime ES2032378T3 (es) 1985-11-27 1986-11-21 Procedimiento para preparar una proteina de fusion.
ES91114411T Expired - Lifetime ES2077747T3 (es) 1985-11-27 1986-11-21 Derivados de hirudina.
ES91114412T Expired - Lifetime ES2073081T3 (es) 1985-11-27 1986-11-21 Proteinas de fusion a base de interleucina-2 e hirudina.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES91114411T Expired - Lifetime ES2077747T3 (es) 1985-11-27 1986-11-21 Derivados de hirudina.
ES91114412T Expired - Lifetime ES2073081T3 (es) 1985-11-27 1986-11-21 Proteinas de fusion a base de interleucina-2 e hirudina.

Country Status (17)

Country Link
EP (3) EP0468539B1 (es)
JP (1) JP2566933B2 (es)
KR (1) KR950000300B1 (es)
AT (2) ATE127841T1 (es)
AU (1) AU595262B2 (es)
CA (1) CA1341203C (es)
DE (4) DE3541856A1 (es)
DK (2) DK172064B1 (es)
ES (3) ES2032378T3 (es)
FI (1) FI93471C (es)
GR (1) GR3005042T3 (es)
HU (1) HU203579B (es)
IE (1) IE59488B1 (es)
IL (1) IL80755A0 (es)
NO (1) NO176481C (es)
PT (1) PT83813B (es)
ZA (1) ZA868943B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3125021A (en) * 1955-11-14 1964-03-17 Smooth
ATE64956T1 (de) * 1984-06-14 1991-07-15 Ciba Geigy Ag Verfahren zur herstellung von thrombininhibitoren.
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
DE3712985A1 (de) * 1987-04-16 1988-11-03 Hoechst Ag Bifunktionelle proteine
DE3819079A1 (de) * 1988-06-04 1989-12-07 Hoechst Ag Hirudin-derivate mit verzoegerter wirkung
DE3835815A1 (de) * 1988-10-21 1990-04-26 Hoechst Ag Neue isohirudine
DE3844211A1 (de) * 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5179196A (en) * 1989-05-04 1993-01-12 Sri International Purification of proteins employing ctap-iii fusions
WO1991000912A1 (en) * 1989-07-07 1991-01-24 Massachusetts Institute Of Technology Production and use of hybrid protease inhibitors
CU22222A1 (es) * 1989-08-03 1995-01-31 Cigb Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
DE3942580A1 (de) * 1989-12-22 1991-06-27 Basf Ag Verfahren zur herstellung von hirudin
US5270181A (en) * 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
DE4140381A1 (de) * 1991-12-07 1993-06-09 Hoechst Ag, 6230 Frankfurt, De Neue synthetische isohirudine mit verbesserter stabilitaet
DE4404168A1 (de) * 1994-02-10 1995-08-17 Hoechst Ag Hirudinderivate und Verfahren zu deren Herstellung
DE59711533D1 (de) 1996-07-26 2004-05-27 Aventis Pharma Gmbh Insulinderivate mit erhöhter Zinkbindung
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
DE10033195A1 (de) * 2000-07-07 2002-03-21 Aventis Pharma Gmbh Bifunktionale Fusionsproteine aus Hirudin und TAP
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
KR101853606B1 (ko) 2009-07-06 2018-05-03 사노피-아벤티스 도이칠란트 게엠베하 메티오닌을 함유하는 수성 인슐린 제제
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
DK108685A (da) * 1984-03-19 1985-09-20 Fujisawa Pharmaceutical Co Vaekstfaktor i
WO1985004418A1 (fr) * 1984-03-27 1985-10-10 Transgene S.A. Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine
EP0158198A1 (en) * 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
DE3429430A1 (de) * 1984-08-10 1986-02-20 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von hirudin und mittel zur durchfuehrung dieses verfahrens
DE3526995A1 (de) * 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
US4865974A (en) * 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase
CA1297003C (en) * 1985-09-20 1992-03-10 Jack H. Nunberg Composition and method for treating animals

Also Published As

Publication number Publication date
CA1341203C (en) 2001-03-13
KR870005098A (ko) 1987-06-04
ATE127841T1 (de) 1995-09-15
FI93471B (fi) 1994-12-30
NO176481B (no) 1995-01-02
PT83813B (pt) 1989-06-30
HUT43642A (en) 1987-11-30
EP0468539A1 (de) 1992-01-29
FI93471C (fi) 1995-04-10
IE59488B1 (en) 1994-03-09
DK52292A (da) 1992-04-21
DE3541856A1 (de) 1987-06-04
FI864798A0 (fi) 1986-11-25
DK172210B1 (da) 1998-01-05
ZA868943B (en) 1987-07-29
EP0227938B1 (de) 1992-04-15
JP2566933B2 (ja) 1996-12-25
EP0468539B1 (de) 1995-09-13
DE3650322D1 (de) 1995-06-14
EP0464867B1 (de) 1995-05-10
HU203579B (en) 1991-08-28
JPS62143696A (ja) 1987-06-26
KR950000300B1 (ko) 1995-01-13
AU595262B2 (en) 1990-03-29
DK52292D0 (da) 1992-04-21
PT83813A (de) 1986-12-01
NO864759D0 (no) 1986-11-26
GR3005042T3 (es) 1993-05-24
DE3684892D1 (de) 1992-05-21
DK172064B1 (da) 1997-10-06
ATE122397T1 (de) 1995-05-15
DE3650396D1 (de) 1995-10-19
NO176481C (no) 1995-04-12
DK568586D0 (da) 1986-11-26
EP0227938A3 (en) 1988-11-23
IE863119L (en) 1987-05-27
FI864798L (fi) 1987-05-28
EP0464867A1 (de) 1992-01-08
ES2077747T3 (es) 1995-12-01
EP0227938A2 (de) 1987-07-08
IL80755A0 (en) 1987-02-27
ES2073081T3 (es) 1995-08-01
AU6569386A (en) 1987-06-04
DK568586A (da) 1987-05-28

Similar Documents

Publication Publication Date Title
ES8506087A1 (es) Procedimiento para preparar proteina de uroquinasa humana bioactiva
DK478786A (da) Cystein-forarmede muteiner af biologisk aktive humantumornekrosefaktorproteiner
ES2056817T3 (es) Transformacion de trichoderma.
DK0574402T3 (da) Ekspression af PACE i værtsceller og fremgangsmåder til anvendelse deraf
MX9203379A (es) Proteinas producidas por los linfocitos humanos, secuencia de adn que codifica para estas proteinas y composiciones farmaceuticas que las contienen.
ES2039263T3 (es) Procedimiento para la extraccion de grasa de proteina de suero.
AR017866A1 (es) Metodo para incrementar las inmunorespuestas de vacunas de acidos nucleicos, composiciones farmaceuticas de aplicacion en dicho metodo, procedimientopara preparar dichas composiciones y vacunas utilizadas en dicho metodo.
ES554155A0 (es) Un procedimiento para la preparacion de un proteina envolvente de un virus de sindrome de inmunodeficiencia adquirida
DK408089D0 (da) Proteiner
DK371087D0 (da) Mamalialt interleukin-4
ES2000278A6 (es) Procedimiento para preparar una proteina de fusion y para preparar una proteina eucariotica.
AR053063A2 (es) Proteina sustancialmente purificada y composicion farmaceutica que la comprende
ES539678A0 (es) Procedimiento para preparar un polipeptido ciclico
ES2123515T3 (es) Antagonistas de citoquinas a base de proteinas virales aisladas.
ES2073081T3 (es) Proteinas de fusion a base de interleucina-2 e hirudina.
FI880017A0 (fi) Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu
ES2007425A6 (es) Un metodo para la produccion de una proteina con actividad inhibidora del crecimiento de tumores.
ES2085928T3 (es) Gen y secuencia proteica del mk humano.
ES2059436T3 (es) Proteina de la membrana exterior f de pseudomonas aeruginosa.
ES2062982T3 (es) Clonaje y expresion del factor de crecimiento de fibroblasto acido.
ATE40556T1 (de) Verfahren zur synthese von peptiden.
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
DK424387D0 (da) Humant placenta angiogen faktor, der er i stand til at stimulere syntesen af papillaer endothelial celleprotease, dna syntese og vandring
AR241713A1 (es) Molecula de dna con una secuencia de bases que codifica la proteina c13 y preparacion de vacunas contra la gripe.
DE69032323D1 (de) Produktion und verwendung von antihelmintischen substanzen und schützenden immunogenen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 227938

Country of ref document: ES